Form 4: Ginkgo Bioworks CEO Granted 5 Million Stock Options with Performance-Based Vesting

Ginkgo Bioworks CEO Jason R. Kelly was granted 5,000,000 stock options tied to performance-based vesting criteria related to stock price hurdles.

Summary

• Jason R. Kelly, CEO of Ginkgo Bioworks Holdings, Inc., was granted 5,000,000 stock options on April 25, 2024.
• These options, referred to as 'Founder Options', have both time-based and performance-based vesting criteria.
• The performance-based vesting is linked to achieving specific stock price hurdles within a five-year period.
• 10% of the options vest upon achieving a 90-calendar-day average stock price of $5.00.
• Another 10% vest upon achieving a 90-calendar-day average stock price of $7.50.
• 20% vest upon achieving a 90-calendar-day average stock price of $10.00.
• The remaining 60% vest upon achieving a 90-calendar-day average stock price of $12.50.
• If any of these performance criteria are met within the five-year period, the options will vest on the five-year anniversary of the grant date, contingent upon Kelly's continued employment with Ginkgo.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as it reflects an incentive structure for the CEO to improve company performance and increase shareholder value. However, the actual benefit depends on achieving the stock price targets.

Positives

• The performance-based vesting structure aligns the CEO's interests with those of the shareholders, incentivizing him to drive up the stock price.
• The long-term vesting schedule (five-year performance period and ten-year expiration) encourages a long-term focus.

Risks

• The performance targets may not be achieved, resulting in the options not fully vesting.
• The value of the options is dependent on the future stock price of Ginkgo Bioworks, which is subject to market fluctuations and company performance.

Future Outlook

The vesting of the options is contingent on the company's stock price performance over the next five years, suggesting an expectation of growth and value creation.

Industry Context

Stock options are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with those of shareholders. The performance-based vesting adds an extra layer of incentive for executives to achieve specific company goals.

Comparison to Industry Standards

• Performance-based stock options are a common practice in the biotech industry to incentivize executives.
• Comparable companies like Amyris or Zymergen (before its acquisition) have used similar equity compensation structures.
• The specific stock price hurdles ($5.00, $7.50, $10.00, $12.50) would need to be compared to the company's historical stock performance and future growth projections to assess their difficulty.

Stakeholder Impact

• Shareholders may view the performance-based options positively, as they align the CEO's interests with increasing shareholder value.
• Employees may be motivated by the potential for company growth and success, which could lead to increased job security and opportunities.

Key Dates